Editor of Patient Care Online.
FDA Grants Priority Review to GSK NDA for First-In-Class Oral Antibiotic
The FDA today accepted GSK's NDA for gepotidacin for the treatment of uncomplicated urinary tract infections in women and adolescents.
FDA Approves Next-Gen Noninvasive CRC Screening Test: Daily Dose
Your daily dose of the clinical news you may have missed.
GLP-1RAs May Lower Risk of Suicidal Ideation for Youth with Obesity, New Data Suggest
In a study of adolescents with obesity, those in the GLP-1RA group had a 33% lower risk of experiencing suicidal ideation or attempts compared with matched controls.
Depression, Anxiety in Youth with Chronic Pain: Daily Dose
October Issue of Patient Care Online Supplement is Now Live
Find details on challenges primary care clinicians face in treating older adults with T2D and an expert discussion on navigating treatments to delay T1D.
Beer and Cider Associated with Higher Risk of Gout in Both Sexes vs Other Alcohol Types
Higher alcohol intake was associated with a greater risk of gout for both sexes, but the correlation was stronger in men than women, according to a recent study.
Effectiveness of Suicide Care Implementation in Primary Care: Daily Dose
RSV Mortality Higher than for Influenza B After Hospital Discharge: Daily Dose
Remdesivir Plus Dexamethasone Reduces Mortality Risk among Adults Hospitalized with COVID-19
Remdesivir plus dexamethasone was associated with reduced 14- and 28-day mortality vs dexamethasone alone, according to a large study of adults hospitalized with COVID-19.
Decrease in MHT Use over Past 2 Decades: Daily Dose
COVID-19 Linked to Long-Term Risk of MACE, Especially Among Adults with non-O Blood Types
Prior SARS-CoV-2 infection was associated with a 2-fold increased risk for MACE for up to 3 years, even among people with no history of CVD, in a new analysis of UK Biobank data.
Preconception Prediabetes in Young Women and Adverse Birth Outcomes: Daily Dose
Survodutide Wins FDA Breakthrough Therapy Designation for Noncirrhotic MASH Treatment in Adults
The safety and efficacy of survodutide in patients with MASH and fibrosis will be assessed in a global pair of phase 3 trials.
FDA Approves First-Ever Biologic Medicine for COPD: Daily Dose
Flu Vaccine Reduced Related Hospitalizations by About One-Third in Southern Hemisphere, but Uptake Still Low
Less than one-quarter of people infected with influenza-associated severe acute respiratory illness were vaccinated, according to a new report.
FDA Approves First-in-Class Schizophrenia Drug: Daily Dose
US Colorectal Cancer Screening Increased Three-Fold among Adults Aged 45-49 Years, but Disparities Persist
Increases in CRC screening were higher in high socioeconomic status and metropolitan areas, according to a new large cohort study.
Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine: Daily Dose
Youth with Chronic Pain Face Greater Symptoms of Depression, Anxiety than Pain-Free Peers
Findings from a systematic review and meta-analysis showed 1 in 3 youth with chronic pain were diagnosed with anxiety and 1 in 8 were diagnosed with depression.
Mental Health Conditions Common in Primary Care Settings: Daily Dose
Novel Oral Antiobesity Drug Reduces Body Weight by up to 13%: Daily Dose
FDA Approves First Self-Administered Flu Vaccine: Daily Dose
Menopausal Hormone Therapy Use Declined in Past 2 Decades among Women Regardless of Age, Race/Ethnicity
Use of menopausal hormone therapy decreased from nearly 27% to 5% among postmenopausal women between 1999 and 2020, according to new research.
Better CV Health in Early Pregnancy Offsets High Genetic Risk: Daily Dose
7 Drugs Approved for Primary Care: Q3 2024
Updated mRNA COVID-19 vaccines, the first orally disintegrating tablet approved for pregnancy prevention, and 5 more.
Atrial Fibrillation More Prevalent in US Than Previously Estimated: Daily Dose
Roflumilast Cream 0.15% Leads to Consistent Improvements in Atopic Dermatitis Across Diverse Skin Types
Roflumilast cream 0.15% was associated with consistent and meaningful improvements in AD clearance and itch reduction, according to new data.
Over Half of US Adults with Uncontrolled HTN Unaware of Their Condition: Daily Dose
Elinzanetant for Menopausal VMS: OASIS Lead Investigator Discusses Results, Side Effects, Next Steps
JoAnn Pinkerton, MD, details the positive findings from the OASIS 1, 2, and 3 studies of elinzanetant and highlights next steps in research.
FDA Approves Lebrikizumab-lbkz for Moderate to Severe AD: Daily Dose
